🇺🇸 FDA
Pipeline program

PIPE-307 Dose A

PIPE 307-201

Phase 2 small_molecule completed

Quick answer

PIPE-307 Dose A for Relapsing Remitting Multiple Sclerosis is a Phase 2 program (small_molecule) at Contineum Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Contineum Therapeutics
Indication
Relapsing Remitting Multiple Sclerosis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials